Edmund Dunn - Jan 2, 2024 Form 4 Insider Report for Monte Rosa Therapeutics, Inc. (GLUE)

Role
Principal Accounting Officer
Signature
/s/ Markus Warmuth, Attorney-in-Fact
Stock symbol
GLUE
Transactions as of
Jan 2, 2024
Transactions value $
$0
Form type
4
Date filed
1/4/2024, 04:15 PM
Previous filing
Aug 18, 2023
Next filing
Jun 5, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GLUE Stock Option (Right to Buy) Award $0 +25K $0.00 25K Jan 2, 2024 Common Stock 25K $5.71 Direct F1
transaction GLUE Stock Option (Right to Buy) Award $0 +35.9K $0.00 35.9K Jan 2, 2024 Common Stock 35.9K $5.71 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of this option shall vest and become exercisable on October 2, 2024, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F2 25% of this option shall vest and become exercisable on January 1, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.